—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
CANCER GENE THERAPY《癌症基因治疗》
月刊 - 英国
  • CANCER GENE THERAPY《癌症基因治疗》
  • SCIE外文期刊
  • 期发文量13
  • 国人占比47.37%
  • 维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:3区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:6
    环比增速:0.00%
  • 期刊信息

  • 研究方向:医学-BIOTECHNOLOGY APPLIED MICROBIOLOGY 生物工程与应用微生物;GENETICS HEREDITY 遗传学;MEDICINE, RESEARCH EXPERIMENTAL 医学:研究与实验;ONCOLOGY 肿瘤学
  • 国际刊号:ISSN 0929-1903;EISSN1476-5500
  • 期刊语言:英语
    出版地区:英国
  • 投稿网址:https://mts-cgt.nature.com/cgi-bin/main.plex
  • 电子邮箱:
  • 期刊官网:https://www.nature.com/cgt/
  • 作者指南:
  • 出版商网址:http://www.nature.com
  • 出版地址:MACMILLAN BUILDING, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW
  • 期刊简介:CANCER GENE THERAPY《癌症基因治疗》(月刊). Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles.

  • 万维提示


  • 1、投稿方式:在线投稿。

    2、期刊网址:https://www.nature.com/cgt/

    3、投稿网址:

    https://mts-cgt.nature.com/cgi-bin/main.plex

    4、官网邮箱:CancerGeneTherapy@us.nature.com

    5、官网电话:+44 (0)20 3192 2216

    6、期刊刊期:月刊,一年出版十二期。

    2021522日星期六

                                 

     

    投稿须知【官网信息】

     

    Guide to Authors

    ABOUT THE JOURNAL

    Aims and Scope

    Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.

    Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

    Journal Details Editor-in-Chief: Georgios Giamas, UK Editorial office: Springer Nature, 4 Crinan Street, London, UK, CancerGeneTherapy@us.nature.com

    Frequency: 12 issues a year

    ARTICLE TYPE SPECIFICATIONS

    ARTICLE DESCRIPTION

    SPECIFICATION

    Article

    These reports of original research should follow the structure outlined below, and should include a clear statement of purpose, a description of the procedures, methods, and subjects or materials used, and a full report of the findings, including discussion, and references to relevant findings of other researchers

    Unstructured abstract max 200 words

    Main body of text (excluding references, figures/tables) not to exceed 12,000 words;

    Max 7 tables or figures;

    Max 60 References

    Review Article Review articles in Cancer Gene Therapy aim to provide accessible, authoritative overviews of a field or topic. Reviews should communicate a sense of enthusiasm, weaving background information with the latest advances, and placing both of these elements in the context of the rest of the field. The abstract describes what the article is about in a succinct, easily digestible way. It should not contain specialist details, abbreviations, references or figure citations. References should concentrate on significant original research papers

    Unstructured abstract max 200 words

    Main body of text (excluding abstract, references, figures/tables) not to exceed 4,000 words

    Max 7 tables or figures;

    Max 120 references

    Brief Communication

    A Brief Communication reports a concise study of high quality and broad interest. Shorter descriptions of important, innovative developments will be considered for preliminary publication.

    Unstructured abstract max 200 words

    Main body of text should be no more than 2 pages

    Max one table or figure

    Max 10 references

    Perspective

    Perspectives are a hybrid between a correspondence and a review, providing an opinion-driven perspective on a particular research topic or field of interest to Cancer Gene Therapy readership. Authors should present a (provocative) view that can be supported by data and literature with the goal of sparking debate and stimulating future research avenues.

    No abstract required

    Main body of text (excluding abstract, references, figures/tables) not to exceed 2,000 words;

    Max 4 tables or figures

    Max 25 references

    Correspondence

    Denotes short, arresting, and timely comments on material published in the journal (including right-of-reply) as well as anything of likely interest to the readers, such as policy debates and community announcements

    No abstract required

    PREPARATION OF ARTICLES

    House Style: Authors should adhere to the following formatting guidelines:

    Text should be double spaced with a wide margin.

    All pages and lines are to be numbered.

    Do not make rules thinner than 1px (0.36mm).

    Use a coarse hatching pattern rather than shading for tints in graphs.

    Colour should be distinct when being used as an identifying tool.

    Commas, not spaces should be used to separate thousands.

    At first mention of a manufacturer, the town (and state if USA) and country should be provided.

    Statistical methods: For normally distributed data, mean (SD) is the preferred summary statistic. Relative risks should be expressed as odds ratios with 95% confidence interval. To compare two methods for measuring a variable the method of Bland & Altman (1986, Lancet 1, 307–310) should be used; for this, calculation of P only is not appropriate.

    Units: Use metric units (SI units) as fully as possible. Preferably give measurements of energy in kiloJoules or MegaJoules with kilocalories in parentheses (1 kcal = 4.186kJ). Use % throughout.

    Abbreviations: On first using an abbreviation place it in parentheses after the full item. Very common abbreviations such as FFA, RNA, need not be defined. Note these abbreviations: gram g; litre l; milligram mg; kilogram kg; kilojoule kJ; megajoule MJ; weight wt; seconds s; minutes min; hours h. Do not add s for plural units.

    Please note that Articles must contain the following components. Please see below for further details.

    Cover letter

    Title page (excluding acknowledgements)

    Abstract

    Introduction

    Materials (or Subjects) and Methods

    Results

    Discussion (including Conclusion)

    Acknowledgements

    Conflict of Interest

    References

    Figure legends

    Tables

    Figures

    Cover Letter Authors should provide a cover letter that includes the affiliation and contact information for the corresponding author. Authors should briefly discuss the importance of the work and explain why it is considered appropriate for the diverse readership of the journal. The cover letter should confirm the material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. If the manuscript has been previously considered for publication in another journal, please include the previous reviewer comments, to help expedite the decision by the Editorial team.

    The cover letter must be on headed notepaper and include the corresponding author’s signature. Please also include a statement confirming that more than one author has directly accessed and verified the data reported in the manuscript.

    Title Page

    The title page must contain:

    Title of the paper - brief, informative, of 150 characters or less and should not make a statement or conclusion

    Full names of all the authors and their affiliations, together with the e-mail address of the corresponding author. If authors regard it as essential to indicate that two or more co-authors are equal in status, they may be identified by an asterisk symbol with the caption ‘These authors contributed equally to this work’ immediately under the address list.

    All authors should provide an institutional email address, this is especially important for the corresponding author and the paper will not proceed through peer review if an institutional email address isn’t provided on the paper and within the submission system, unless there is a legitimate reason why the corresponding author cannot provide one.

    ……

    更多详情:

    https://www.nature.com/cgt/authors-and-referees/gta



欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码